ArticlePharmacoEconomics - open2023

Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland.

Esra Çakar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.